Retro Biosciences

“Sam Altman’s $1B aging company — autophagy, plasma, reprogramming under one roof.”

Retro took a huge check to compress cellular aging programs (including autophagy and reprogramming) into a company that is supposed to move fast.

The other giant check on the therapeutics wall.

Series B+. Filed from the Top Tier Impact landscape.

A billion for ten years.

Also in this file